Company / Operating Income
Edgewise Therapeutics, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$191.4M
FY2025
5-year range
-$191.4M / -$43.2M
FY2021-FY2025
Trend
-20.5%
vs FY2024
Sector context
#140 of 204
Health Care
What the data says
At -$191M, Edgewise Therapeutics, Inc.'s operating income ranks #140 of 204 in the Health Care sector. Operating Income has declined for 5 consecutive years, from -$17M in FY2020 to -$191M in FY2025.
Based on SEC 10-K filings.
-$191M in FY2025.
Declined from -$114M to -$191M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#140 of 204 in Health CareTop 69% of 204This company -$191.4M Sector average $107.8M
▼
-277.6% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 20.5% year-over-year.
- Ranks #140 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$191.4M | -20.5% |
| FY2024 | -$158.8M | -38.9% |
| FY2023 | -$114.4M | -59.6% |
| FY2022 | -$71.7M | -65.8% |
| FY2021 | -$43.2M | -151.4% |
| FY2020 | -$17.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026